• PDF / 273,941 Bytes
• 16 Pages / 439.37 x 666.142 pts Page_size
• 80 Downloads / 211 Views

DOWNLOAD

REPORT

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3246

2

Incidence of ITP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3247

3

Treatment of Adults ITP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3248

4

Treatment of Children ITP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3249

5

The Necessity of QOL Evaluation in ITP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3250

6 The Development and Evaluation of Quality of Life Instruments in ITP . . . . . . . 3251 6.1 Quality of Life Instruments in Adults with ITP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3251 6.2 Quality of Life Instruments in Children with ITP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3253 7 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8

Quality of Life Assessing in ITP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3255 Duration of Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3255 Platelet Count . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3255 Bleeding Events . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3256 Fear of Serious Hemorrhage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3256 Side Effects of Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3257 Splenectomy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3257 Economic Burden . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3258 Family . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3258 Summary Points . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3258

#

Springer Science+Business Media LLC 2010 (USA)

3246

188

Quality of Life in Immune Thrombocytopenic Purpura: China Perspectives

Abstract: Idiopathic thrombocytopenic purpura (ITP) is classified as an autoimmune bleeding disease. It is characterized by mucocutaneous bleeding due to the low platelet count. For achieving hemostatic platelet counts, main treatment measur

Recommend Documents

Dapsone Induced Agranulocytosis and Hemolytic Anemia in Immune Thrombocytopenic Purpura

165 102 120KB

Severe immune thrombocytopenic purpura in critical COVID-19

174 62 585KB

Diagnosis and Management of Thrombotic Thrombocytopenic Purpura

150 104 28MB

Romiplostim: a guide to its use in immune (idiopathic) thrombocytopenic purpura

165 24 95KB

Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrosp

163 21 574KB

Retinal involvement in acute thrombotic thrombocytopenic purpura: a case report

212 121 571KB

Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-labe

168 2 978KB

Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study

165 110 895KB

Thrombotic thrombocytopenic purpura developed during the conservative treatment of anti-phospholipase A 2 receptor antib

153 16 1MB

Concomitant thrombotic thrombocytopenic purpura and ANCA-associated vasculitis in an adolescent

151 39 168KB

Quality of Life Among Diabetic Subjects: Indian Perspectives

186 75 57MB

Quality of Life and Age Urinary Incontinence Severity: Turkish Perspectives

151 43 57MB